Transparency Life Sciences pioneered open sourcing design of clinical trial protocols and was one of the first to execute ‘virtual’ studies; implementation of their model will enable true patient-centric clinical research.
-Jeffrey Kasher, President, Patients Can’t Wait, LLC; former VP and COO, Global Clinical Development Organization, Eli Lilly and Company
We applaud Transparency Life Sciences for being a valued partner of our Foundation, and for creating a model in which patients are more than subjects, but thoughtful collaborators in clinical trial design and execution.
-Ginger Spitzer, Executive Director, Foundation for Sarcoidosis Research
Transparency Life Sciences’ crowdsourcing expertise obtained fresh insights for our protocol assessing metformin in prostate cancer. Their commitment to all-digital clinical trials will benefit patients and investigators, and help achieve more efficient and more informative clinical trials.
-Dr. Matthew Galsky, Professor of Hematology-Oncology, Mt. Sinai School of Medicine